Risky car following in abstinent users of MDMA.
Ecstasy (MDMA) use raises concerns because of its association with risky driving. We evaluated driving performance and risk taking in abstinent recreational MDMA users in a simulated car following task that required continuous attention and vigilance. Drivers were asked to follow two car lengths behind a lead vehicle (LV). Three sinusoids generated unpredictable LV velocity changes. Drivers could mitigate risk by following further behind the erratic LV. From vehicle trajectory data we performed a Fourier analysis to derive measures of coherence, gain, and delay. These measures and headway distance were compared between the different groups. All MDMA drivers met coherence criteria indicating cooperation in the car following task. They matched periodic changes in LV velocity similar to controls (abstinent THC users, abstinent alcohol users, and non-drug users), militating against worse vigilance. While all participants traveled approximately 55 mph (89 kph), the MDMA drivers followed 64 m closer to the LV and demonstrated 1.04 s shorter delays to LV velocity changes than other driver groups. The simulated car following task safely discriminated between driving behavior in abstinent MDMA users and controls. Abstinent MDMA users do not perform worse than controls, but may assume extra risk. The control theory framework used in this study revealed behaviors that might not otherwise be evident.
Dastrup
Elizabeth
E
Department of Biostatistics, University of Iowa, Iowa City, IA, USA.
Lees
Monica N
MN
Bechara
Antoine
A
Dawson
Jeffrey D
JD
Rizzo
Matthew
M
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D000328:Adult; D001288:Attention; D001334:Automobile Driving; D001336:Automobiles; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced; D005260:Female; D005583:Fourier Analysis; D006213:Hallucinogens / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D013287:Illicit Drugs; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects* / Q000494:pharmacology; D018570:Risk Assessment; D012309:Risk-Taking; D012449:Safety; D013223:Statistics as Topic; D018709:Statistics, Nonparametric; D055815:Young Adult
D018759:Adrenergic Uptake Inhibitors; D006213:Hallucinogens; D013287:Illicit Drugs; D018817:N-Methyl-3,4-methylenedioxyamphetamine
Addiction. 2006 Nov;101(11):1614-21
17034441
Psychopharmacology (Berl). 2000 Oct;152(3):230-48
11105933
Ann Intern Med. 2000 Oct 17;133(8):656; author reply 657-8
11033599
Ann Intern Med. 2000 Mar 7;132(5):354-63
10691585
Lancet. 1992 Aug 15;340(8816):384-7
1353554
J Psychopharmacol. 2006 Mar;20(2):302-11
16510488
J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):719-25
10811694
Nat Neurosci. 2005 Nov;8(11):1458-63
16251988
Psychopharmacology (Berl). 1999 Apr;143(4):417-25
10367560
Psychopharmacology (Berl). 1998 Oct;139(3):261-8
9784083
Psychopharmacology (Berl). 2004 May;173(3-4):440-5
14714102
Ned Tijdschr Geneeskd. 1994 Sep 10;138(37):1850-5
7935920
Am J Drug Alcohol Abuse. 1992;18(3):331-41
1357957
J Forensic Sci. 2001 Nov;46(6):1426-33
11714155
J Psychopharmacol. 1998;12(1):79-83
9584971
Psychopharmacology (Berl). 1999 Jan;141(1):30-6
9952062
Neurology. 1998 Dec;51(6):1532-7
9855498
J Gambl Stud. 2003 Spring;19(1):23-51
12635539
Hum Psychopharmacol. 2001 Dec;16(8):557-577
12404536
Psychopharmacology (Berl). 2001 Jan 1;153(2):196-202
11205419
Psychopharmacology (Berl). 2006 Sep;187(4):467-75
16830130
Psychopharmacology (Berl). 2005 May;179(3):559-66
15723231